3 new cardiac treatment alternatives

July 29, 2013

Internationally acknowledged as being constantly at the cutting edge with the most modern medical technology, the Pasteur Clinic’s interventional cardiology department has in recent weeks been applying new techniques which represent genuine medical advances for patients with certain cardiac diseases.


First subcutaneous cardiac defibrillator implants in the region


The cardiac rhythmology team has successfully implanted a new generation of cardiac fibrillators in two patients. Without this innovative device, these patients would have had to undergo major invasive surgery. For patients with severe cardiac disease who are at high risk of sudden death, the subcutaneous placement makes this new device an alternative solution to the vascular approach when the latter can no longer be used. With the benefit of expertise and experience based on over 150 defibrillator implantations annually, the Pasteur Clinic is among the very first centres in France to have used this new generation of fibrillators, which are still not yet widely available in France or even Europe.


First implant in the region for CVA prevention


Among the complications in patients with atrial fibrillation, the most threatening is blood clot formation, primarily in the left atrial appendage (auricle) of the heart, with embolisation and the onset of a CVA. Anticoagulants are the treatment most commonly prescribed to reduce these risks. Until now, there were no solutions for patients contraindicated for oral anticoagulant therapy. As of now, there is a new interventional procedure, the technique for percutaneous left atrial appendage closure. It consists in implanting a prosthesis in this appendage. This operation represents a genuine alternative to anticoagulant therapy.



As the national referral centre for cardiac rhythmology, in both the private and public sectors, the Pasteur Clinic is the 1st health institution in the Midi-Pyrénées region to use this technique.


One of the first private centres to perform a percutaneous pulmonary valve implant


The pulmonary valve, located between the right ventricle and the pulmonary artery, is affected by a number of congenital cardiac malformations, either native or following post-surgical correction. Previously, only one option was available to these patients: open-heart surgery to replace the deficient pulmonary valve. With its expertise in interventional catheterisation, the Pasteur Clinic is among the first centres in France to obtain accreditation to perform percutaneous implantations of pulmonary valves in adultcongenital heart patients.


This newest technique is a genuine alternative to open-heart surgery.